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Purpose: To determine the efficacy and safety of treating predominantly hemorrhagic 
age-related macular degeneration (AMD) with transconjunctival sutureless vitrectomy (TSV), 
tissue plasminogen activator (tPA), sulphur hexafluoride (SF6), and intravitreal bevacizumab.
Methods: Retrospective study, consecutive case series. Patients with acute hemorrhagic AMD 
treated with 25- or 23-gauge TSV, subretinal or intravitreal tPA, fluid-air-SF6 exchange and 
intravitreal injection of bevacizumab. All operations were performed within the first 5 days after 
the start of symptoms, which consisted of visual acuity (VA) loss and central scotoma.
Results: Fifteen eyes from 15 patients were included. The patients’ mean age was 79.6 years, 
and the mean follow-up was 11.8 months. Five patients (33%) were receiving oral anticoagulant 
treatment. At baseline, the mean VA (logMAR values) was 1.5 (20/640 Snellen equivalent). At the 
last follow-up visit, the mean VA was 1.1 (20/250) (P  0.0001; paired t-test). The submacular 
hemorrhage was successfully displaced in all the cases. Complications consisted of three cases 
of vitreous hemorrhage and a tear or the retinal pigment epithelium. Twelve cases (80%) did 
not require further treatment during the follow-up period.
Conclusion: A surgical approach with 25- or 23-gauge TSV, tPA, SF6 and intravitreal bevaci-
zumab is an efficacious and safe procedure in patients with hemorrhagic AMD. Early treatment 
is advisable for obtaining the optimal outcome.
Keywords: Hemorrhagic age-related macular degeneration, tissue plasminogen activator, 
intravitreal bevacizumab; transconjunctival sutureless vitrectomy
Introduction
Submacular hemorrhages can arise from retinal or choroidal circulation associated 
with age-related macular degeneration (AMD), arterial macroaneurysms and severe 
traumas. Several factors, such as a release of toxins, tractional forces acting on the 
retina and a diffusion barrier created by the hemorrhage can promote photoreceptor 
damage and a loss of visual acuity (VA).1
To date, intravitreal injections of anti-vascular endothelial growth factor (anti-
VEGF) drugs have been the gold standard for the treatment of choroidal neovasculariza-
tion (CNV) secondary to AMD. Notwithstanding, clinical trials used for drug approval, 
such as the MARINA and ANCHOR studies of ranibizumab, excluded patients with 
predominantly hemorrhagic lesions.2
In contrast, the Submacular Surgery Trial did not report favorable results in patients 
with subfoveal hemorrhagic lesions secondary to neovascular AMD.3Clinical Ophthalmology 2010:4 68
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Photodynamic therapy (PDT) with verteporfin has been 
proven, with limited success, in these patients as well.4
Peyman and colleagues5 were the first to report the suc-
cess of a subretinal injection of tPA in five patients with 
submacular hemorrhages related to arterial macroaneurysms 
and AMD. They claimed that tPA administration reduced the 
surgical manipulation of the retina and allowed a smaller 
retinotomy to drain the blood.
Since then, several techniques have been described. 
Some have proposed pneumatic displacement of the hem-
orrhage combined with subretinal tPA and gas.6,7 Olivier 
and colleagues8 published a study of 29 eyes in 28 patients, 
using this technique to treat thick submacular hemorrhages 
secondary to AMD. They achieved a total displacement of 
the subfoveal blood in 25 cases and 17 eyes gained 2 lines 
of VA. Reported complications included two cases of vitreous 
hemorrhage that cleared within 4 weeks.
Other authors have proposed that intravitreal injections 
of tPA and expansile gas can be used without vitrectomy.9 
Chen and colleagues10 used this treatment to obtain satisfac-
tory results in 104 eyes, although they reported eight cases of 
vitreous hemorrhage and three cases of retinal detachment.
Other techniques described in the literature include 
pneumatic displacement without tPA11 and the preoperative 
intravitreal injection of tPA.12
A recent study found favorable results with a triple injec-
tion of tPA, gas, and bevacizumab without vitrectomy.13
The aim of the present study was to determine the efficacy 
and safety of the treatment of hemorrhagic AMD with 25- or 
23-gauge transconjunctival sutureless vitrectomy (TSV), tPA, 
sulphur hexafluoride (SF6), and intravitreal bevacizumab.
Methods
This is a retrospective study comprised of consecutive case 
series of patients with submacular, predominantly hemor-
rhagic lesions (blood  50% of total lesion size) secondary 
to neovascular AMD. Patients were operated at the Institut 
de la Màcula i de la Retina and at the Hospital Universitari 
de Bellvitge between May 2007 and November 2008. All the 
included patients had been diagnosed of neovascular AMD. 
Based on clinical features of previously treated patients and 
status of the fellow eye we did not identify any polypoidal 
choroidal vasculopathy or any other cause of submacular 
hemorrhage.
A single surgeon (LA) operated on all of the recruited 
patients within the first 5 days after the beginning of the 
symptoms, which consisted of VA loss and a central scotoma. 
A 25- or 23-gauge TSV was performed under retrobulbar 
anesthesia with posterior hyaloid dissection. In cases with a 
thick submacular hemorrhage, two or three retinotomies were 
performed with subretinal injection of tPA (concentration of 
125 mg/mL of balance salt solution) using a 39-gauge tip 
cannula. Subsequently, a fluid-air-20% SF6 exchange was 
performed with a final intravitreal injection of bevacizumab. 
In cases with a flat submacular hemorrhage, an intravitreal 
injection of tPA was administered after the fluid-air-gas 
exchange. A thick hemorrhage was defined as one causing a 
significant bulging and elevation of the macular surface from 
the posterior pole plane (Figure 1).
Patients were left lying on their back for 1 hour after 
the surgical procedure, and were subsequently instructed 
to keep a face-down position for 3 days. Follow-up visits 
were performed 24 hours and 1 week after the surgery, and 
a)
b)
Figure 1 Female aged 89 years (patient no. 5). Baseline fundus photograph (a) and 
2 months after the surgery (b).   Visual acuity improved from 20/1000 to 20/400. no 
further treatment was needed during the 12-month follow-up.Clinical Ophthalmology 2010:4 69
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then monthly. They included VA measurement using Early 
Treatment Diabetic Retinopathy Study (ETDRS) charts, 
anterior segment examination, intraocular pressure measure-
ment, funduscopic examination and retinographies. Addi-
tional fluorescein angiography (FA) and optical coherence 
tomography (OCT) scans were performed at the investigator’s 
discretion.
During follow-up examinations, patients who exhibited 
CNV activity were treated, as usual, with intravitreal injec-
tions of anti-VEGF agents.
Results
The present study included 15 eyes of 15 patients; 10 women 
(67%) and five men (33%). The affected eye was right in 
eight cases (53%) and left in seven cases (47%). Six patients 
(40%) were phakic, eight patients (53%) were pseudophakic 
and one patient (7%) was aphakic. Eleven patients (73%) had 
an advanced AMD in the fellow eye and one patient (7%) had 
lost vision in the other eye due to a neovascular glaucoma 
secondary to a central retinal vein occlusion (Table 1).
The mean age of the patients was 79.6 years (standard 
deviation [SD]: 8.6 years; range: 62–94 years). The mean 
follow-up after the surgery was 11.8 months (SD: 8.3 months; 
range: 3–24 months).
Eight patients (53%) had been previously treated in the 
study eye with PDT or intravitreal injections of anti-VEGF 
drugs (Table 1).
Five patients (33%) were receiving treatment with oral 
anticoagulant drugs for heart arrhythmia. Four of the five 
patients under coumadin therapy were among the cases with 
the most massive bleeds (Table 1).
Three of the operations (20%) were performed using 
23-gauge TSV and 12 cases (80%) using 25-gauge TSV. 
Combined cataract surgery consisting of phakoemulsification 
plus intraocular lens was performed in two cases (13%).
In eight cases (53%) with thick submacular hemorrhage 
we performed subretinal injection of tPA (Figure 1), and in 
the other seven cases (47%), characterized by flat submacular 
hemorrhage, an intravitreal injection of tPA was administered 
after the fluid-air-gas exchange (Figure 2).
Lesion size ranged from 15 mm2 (5.5 disc areas) to 
41 mm2 (15 disc areas). The mean lesion size was 33.1 mm2 
(SD: 4.2 mm2) in the patients with thick submacular hemor-
rhages and 19.4 mm2 (SD: 3.3 mm2) in the patients with flat 
submacular hemorrhages.
The submacular hemorrhage was successfully dis-
placed in all cases. At baseline, the mean VA (logMAR 
values) was 1.5 (SD: 0.2) (20/640 Snellen equivalent). At 
the last follow-up visit, the mean VA was 1.1 (SD: 0.3) 
(20/250 Snellen equivalent) (P  0.0001; paired t-test). 
The mean VA (ETDRS) improved from 9.4 letters to 28.2 
letters with a mean change of +18.7 letters (P  0.0001; 
paired t-test). Eleven patients (73%) gained 15 or more 
letters of VA.
Table 1 Characteristics of patients included in the study
Patient  Sex  Age  Eye  Lens status  Fellow eye  Anti-coagulant 
treatment
Previous  
treatment
Macular  
hemorrhage
Lesion size 
1 Female 70 yo Left Pseudo-phakic Disciform scar Coumadin no Thick 32 mm2
2 Male 78 yo Left Phakic Disciform scar no no Flat 15 mm2
3 Male 83 yo Right Pseudo-phakic normal Coumadin 4 Lucentis Thick 35 mm2
4 Male 94 yo Right Pseudo-phakic Disciform scar no no Thick 31 mm2
5 Female 89 yo Right Pseudo-phakic Atrophic AMD no no Thick 41 mm2
6 Female 62 yo Right Phakic Wet AMD no no Flat 18 mm2
7 Female 88 yo Right Phakic Disciform scar no no Flat 23 mm2
8 Female 76 yo Left Pseudo-phakic Wet AMD no 3 Macugen Flat 20 mm2
9 Female 86 yo Left Pseudo-phakic Disciform scar Coumadin 3 Lucentis Thick 34 mm2
10 Female 75 yo Left Phakic Disciform scar Coumadin 1PDT 2 Macugen  
3 Avastin
Flat 24 mm2
11 Male 82 yo Left Phakic Lost by glaucoma no 1 PDT 3 Lucentis Flat 20 mm2
12 Female 75 yo Right Pseudo-phakic Wet AMD no 3 Lucentis Flat 16 mm2
13 Male 89 yo Left Aphakic Wet AMD Coumadin 1 Lucentis Thick 32 mm2
14 Female 71 yo Right Pseudo-phakic normal no 3 Lucentis Thick 34 mm2
15 Female 77 yo Right Phakic normal no no Thick 26 mm2
Abbreviations: AMD, age-related macular degeneration; PDT, photodynamic therapy; yo, years old.Clinical Ophthalmology 2010:4 70
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Complications consisted of three cases (20%) of vitreous 
hemorrhage that spontaneously resolved after 2–3 weeks. 
Additionally, one patient (7%) had a tear of the retinal pig-
ment epithelium (RPE) (Figure 3).
Twelve cases (80%) did not require further treatment 
during the follow-up period. Three cases (20%) were treated 
with additional intravitreal injections of anti-VEGF drugs 
(Table 2).
Discussion
The present study found a favorable outcome of managing 
predominantly hemorrhagic lesions, secondary to AMD, with 
TSV combined with tPA, SF6, and intravitreal bevacizumab. 
The submacular hemorrhage was successfully displaced 
in all cases, and the mean VA significantly improved after 
surgical treatment.
Recently, Meyer and colleagues13 published a study using 
a triple intravitreal injection of tPA, gas and bevacizumab 
without vitrectomy in 19 patients with acute subretinal hem-
orrhages. The initial size of the lesion was 1–3 disc diameters. 
In our study, lesion size was bigger, ranging from 15 mm2 (5.5 
disc areas) to 41 mm2 (15 disc areas). In their study, the mean 
VA improved significantly from 20/133 at baseline to 20/74 at 
3 months. In our study, the mean VA improved from 20/640 
to 20/250. However, the mean ETDRS VA improvement was 
very similar in both studies (3.7 lines in their study compared 
with 3.6 lines in ours). Thus, a surgical approach in large 
lesions can obtain comparable results to a triple intravitreal 
injection procedure in smaller hemorrhagic lesions.
In our study, 33% of patients received oral anticoagulants. 
It is known that this medication significantly increases the risk 
of an intraocular hemorrhage in wet AMD patients.14
a) b)
Figure 2 Female aged 76 years (patient no. 8). Baseline fundus photograph (a) and 12 months after the surgery (b). Visual acuity improved from 20/800 to 20/200. no further 
treatment was needed during the 20-month follow-up.
a) b)
Figure 3 Male aged 83 years (patient no. 3). Baseline fundus photograph (a) and 2 weeks after the surgery showing a tear of the retinal pigment epithelium (b).Clinical Ophthalmology 2010:4 71
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intravitreal injection of bevacizumab. Their study showed that 
tPA and bevacizumab are compatible drugs with no evidence 
of retinal toxicity. Moreover, the potent antiangiogenic effect 
associated with bevacizumab could be beneficial for reducing 
CNV activity. In fact, 80% of patients in our study did not 
require further treatment during the follow-up period. How-
ever, no strong evidence suggests bevacizumab is associated 
with more prompt or thorough lesion regression.
The only complications we detected were three cases of 
mild vitreous hemorrhage that spontaneously cleared within 
the first few weeks. It is logical that the liquefied subretinal 
blood enters the vitreous cavity to get reabsorbed posteriorly. 
None of our patients had a retinal tear or retinal detachment.
We observed a single tear of the RPE after resolution 
of the submacular hemorrhage. It was not clear whether 
the tear was present preoperatively or developed after 
the surgery. RPE rips have been described in large submacular 
hemorrhages in wet AMD patients.16
All operations were performed within the first 5 days 
after the patients first experienced symptoms. Olivier and 
colleagues8 reported an average submacular hemorrhage 
duration of 23 days before surgery. Meyer and colleagues13 
reported a mean duration of symptoms of 9 days (range: 
4–12 days). We believe that optimal results in these cases are 
Table 2 Main results of the study
Patient 
 
Surgery 
 
tPA 
 
Baseline  
VA logMAR 
(Snellen)
Baseline  
VA ETDRS 
Final VA  
logMAR  
(Snellen)
Final VA  
ETDRS 
Complications 
 
Posterior 
treatment 
Follow-up 
(months) 
1 PPV 25 g subretinal 1.7 (20/1000) 4 letters 1.3 (20/400) 20 letters no no 12
2 PPV 25 g intravitreal 1.6 (20/800) 8 letters 1.1 (20/250) 30 letters no 3 Lucentis 24
3 PPV 23 g subretinal 1.6 (20/800) 8 letters 1.3 (20/400) 20 letters RPe tear no 7
4 PPV 25 g subretinal 1.7 (20/1000) 4 letters 1.3 (20/400) 20 letters Vitreous  
hemorrhage
no 8
5 PPV 25 g subretinal 1.7 (20/1000) 4 letters 1.3 (20/400) 20 letters Vitreous  
hemorrhage
no 12
6 PPV 25 g intravitreal 0.7 (20/100) 50 letters 0.1 (20/25) 80 letters no 3 Avastin 24
7 Phako+iOLPPV 23 g intravitreal 1.6 (20/800) 8 letters 1.3 (20/400) 20 letters no no 20
8 PPV 25 g intravitreal 1.6 (20/800) 8 letters 1 (20/200) 35 letters no no 20
9 PPV 25 g subretinal 1.7 (20/1000) 4 letters 1.3 (20/400) 20 letters Vitreous  
hemorrhage
no 6
10 Phako+iOL PPV 25 g intravitreal 1.7 (20/1000) 4 letters 1.3 (20/400) 20 letters no no 24
11 PPV 25 g intravitreal 1.3 (20/400) 20 letters 0.6 (20/80) 55 letters no 2 Lucentis 8
12 PPV 23 g intravitreal 1.6 (20/800) 8 letters 1.3 (20/400) 20 letters no no 3
13 PPV 25 g subretinal 1.7 (20/1000) 4 letters 1.3 (20/400) 20 letters no no 3
14 PPV 25 g subretinal 1.7 (20/1000) 4 letters 1 (20/200) 35 letters no no 3
15 PPV 25 g subretinal 1.7 (20/1000) 4 letters 1.6 (20/800) 8 letters no no 3
Abbreviations: eTDRs, early treatment diabetic retinopathy study; PPV, pars plana vitrectomy; tPA, tissue plasminogen activator;   VA, visual acuity.
We decided to perform a posterior vitrectomy to minimize 
the risk of vitreoretinal tractions that could be associated with 
the single administration of intravitreal injections. In addition, 
a surgical approach seems advisable taking into account the 
large size of the lesions included in our study. Current systems 
of microincisional TSV allow efficacious, safe and swift sur-
gery with minimal eye trauma and discomfort for the patient. 
However, we do not think that 25 g or 23 g vitrectomy may 
achieve better anatomical or functional outcome compared 
with that using 20 g instruments.
In cases of thick submacular hemorrhages, we injected 
subretinal tPA as previously described by Olivier and col-
leagues.8 In cases of flat submacular hemorrhages, we 
decided to perform an intravitreal tPA injection to reduce 
possible damage to photoreceptors and RPE cells associated 
with subretinal manipulation. The final results were better 
in the patients with flat submacular hemorrhages than in the 
patients with thick hemorrhages. This could be related to the 
smaller lesion size in the patients with flat hemorrhages.
We used SF6 because we believe that a short-acting gas 
is sufficient to obtain an adequate pneumatic displacement 
of the submacular hemorrhage.
In accordance with an experimental study published 
by Lüke and colleagues,15 we decided to administer a final Clinical Ophthalmology 2010:4
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dependent upon early surgery to avoid irreversible damage 
to photoreceptors and RPE cells.
Limitations of this study are that it was retrospective, 
noncomparative, nonrandomized and included few patients 
with a limited follow-up. It is difficult to enroll a large number 
of cases with this macular disorder.
In conclusion, this small study has shown efficacy and 
safety in the management of predominantly hemorrhagic 
AMD lesions with an early TSV with tPA, gas and intravitreal 
bevacizumab.
Larger multicenter randomized studies are warranted 
to determine the real therapeutic effect of this surgical 
approach.
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